Anixa Fortifies Global IP for Ovarian Cancer Prevention Vaccine

SAN JOSE, CA – June 01, 2026 – Anixa Biosciences has bolstered its international intellectual property for a novel ovarian cancer vaccine, securing a Notice of Allowance from the Canadian Intellectual Property Office. The move strengthens the company's position as it advances a technology that aims to prevent one of the deadliest cancers affecting women, particularly those at high genetic risk.

The allowed patent covers the core methodology of the vaccine: using a nucleic acid-based composition to train the immune system to recognize and attack cells associated with ovarian cancer. This technology, exclusively licensed from the world-renowned Cleveland Clinic, is being co-developed with the National Cancer Institute (NCI), adding significant institutional weight to the program.

This Canadian milestone is the latest in a series of strategic patent victories for the San Jose-based biotechnology firm. It follows the issuance of a foundational U.S. patent in July 2025 and positive patent decisions in Europe and Japan, collectively building a global intellectual property fortress around the promising vaccine candidate.

"This Canadian Notice of Allowance further strengthens the international patent protection around our ovarian cancer vaccine program and supports the novelty of our AMHR2-targeted immunoprevention approach," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Together with our U.S. patent protection for ovarian cancer vaccine technology and our separate intellectual property portfolio for breast cancer vaccine technology, this allowance supports our strategy of building a broad cancer vaccine platform based on retired-protein targets."

A New Paradigm: The 'Retired Protein' Strategy

At the heart of Anixa's approach is an elegant and innovative scientific concept known as the 'retired protein' strategy. This immunoprevention model, pioneered at Cleveland Clinic, targets proteins that are essential during certain life stages but become 'retired'—or cease to be expressed—in normal, healthy adult tissue.

The ovarian cancer vaccine specifically targets the anti-Müllerian hormone receptor 2 (AMHR2). This protein is normally expressed on the surface of ovarian cells before menopause but its presence naturally wanes as a woman ages. Critically, scientific research has shown that AMHR2 is aberrantly re-expressed in the majority of epithelial ovarian cancers, the most common form of the disease. By immunizing against AMHR2, the vaccine aims to teach the body's immune system to identify and eliminate these cancerous or pre-cancerous cells that display the 'retired' protein, while leaving healthy tissues unharmed.

This targeted approach holds the potential to circumvent a major hurdle in cancer immunotherapy: the risk of autoimmune reactions where the immune system attacks healthy cells. Because AMHR2 is largely absent in healthy post-menopausal women, the vaccine could theoretically provide a powerful surveillance mechanism against emerging tumors with a high degree of safety. Preclinical studies have already shown that vaccination against a part of the AMHR2 protein can significantly inhibit tumor growth and improve survival, providing a strong foundation for its move toward human trials.

Addressing a Critical Unmet Need

The potential impact of a successful preventative vaccine cannot be overstated. Ovarian cancer is often called a 'silent killer' because its early symptoms are vague and easily dismissed, leading to diagnosis in advanced stages for the majority of patients. According to global health data, there were over 324,000 new cases and nearly 207,000 deaths from ovarian cancer in 2022 alone. Projections indicate these numbers could surge by over 50% by 2050.

For high-risk populations, the situation is particularly dire. Women carrying BRCA1 or BRCA2 gene mutations face a dramatically elevated lifetime risk of developing ovarian cancer. Currently, their primary preventative option is a prophylactic oophorectomy—the surgical removal of their ovaries and fallopian tubes. While effective, this is a drastic and irreversible procedure with significant consequences for quality of life, including surgically-induced menopause.

Anixa’s vaccine represents a beacon of hope for a less invasive, more targeted prophylactic strategy. If successful, it could shift the paradigm from surgical prevention and late-stage treatment to proactive immunological protection, offering a powerful new tool for women and their physicians in managing cancer risk.

Building a Platform for the Future of Cancer Vaccines

The progress with the ovarian cancer vaccine does not exist in a vacuum. It is a key component of Anixa's broader strategy to build a versatile cancer immunization platform based on the 'retired protein' concept. The company's breast cancer vaccine, which targets a different retired protein called alpha-lactalbumin, recently provided powerful validation for the entire platform.

That vaccine successfully completed a Phase 1 clinical trial, funded by the U.S. Department of Defense and conducted with Cleveland Clinic. The trial met all its primary endpoints, demonstrating that it was well-tolerated and capable of generating a robust immune response against the target protein. Anixa is now planning to advance the breast cancer vaccine into a Phase 2 study in late 2026, a critical step toward proving its efficacy.

The success of the breast cancer trial de-risks the underlying technology and bolsters confidence in the ovarian cancer program, which is following a similar developmental path. Beyond these programs, Anixa is exploring the application of this strategy to other intractable adult-onset cancers, including those of the lung, colon, and prostate.

While the competitive landscape for cancer treatments is crowded with therapies for existing disease, Anixa has carved out a distinct niche by focusing on prevention. As the company methodically constructs its global patent shield and advances its clinical programs, it is positioning itself not just as a developer of a single product, but as a potential leader in the next generation of cancer immunoprevention.